Moreover, in a prospective clinical trial of stage IV lung adenocarcinoma with mutated EGFR, the addition of bevacizumab to the standard tyrosine kinase inhibitor (TKI) treatment increased progression free survival and reduced BM formation [24]. Here, EGFR is linked to lung adenocarcinoma.